Antimicrobial Activity of the Pleuromutilin Antibiotic BC-3781 against Bacterial Pathogens Isolated in the SENTRY Antimicrobial Surveillance Program in 2010
Antimicrobial Activity of the Pleuromutilin Antibiotic BC-3781 against Bacterial Pathogens Isolated in the SENTRY Antimicrobial Surveillance Program in 2010
复制标题
DOI：
10.1128/aac.00358-13
复制
发表时间：
2013-09-01
影响因子：
4.9
通讯作者：
Jones, Ronald N.
中科院分区：
文献类型：
--
作者：
Paukner, Susanne;Sader, Helio S.;Jones, Ronald N.
BC-3781是一种新型的半合成截胸素类抗生素，可抑制细菌蛋白质合成。BC-3781已经完成了治疗急性细菌性皮肤和皮肤结构感染(ABSSSI)的第二阶段临床试验。其抗菌谱还涵盖了导致社区获得性细菌性肺炎(CABP)的主要病原体。在这项研究中，BC-3781的抗菌活性与2010年在全球哨兵抗菌监测计划中收集的10,035株主要引起ABSSSI和CABP等感染的细菌分离株进行了比较。BC-3781对金黄色葡萄球菌(MIC50/90，0.12/0.12微克/毫升；
BC-3781 is a novel semisynthetic pleuromutilin antibiotic inhibiting bacterial protein synthesis. BC-3781 has completed a phase 2 clinical trial in acute bacterial skin and skin structure infections (ABSSSI). Its antibacterial spectrum additionally covers the predominant pathogens causing community-acquired bacterial pneumonia (CABP). In this study, the antibacterial activity of BC-3781 was evaluated against a contemporary collection of 10,035 bacterial isolates predominately causing ABSSSI and CABP, among other infections, collected within the SENTRY Antimicrobial Surveillance Program worldwide in 2010. BC-3781 exhibited potent activity against organisms commonly isolated from ABSSSI such as Staphylococcus aureus (MIC50/90, 0.12/0.12 mu g/ml; 99.8% inhibited at